10x GenomicsTXG +1.85%62 Days Inventory is 112.19 as of Mar. 2026, which is 21% below its 10-year median of 141.18. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.98 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 495 Healthcare Providers & Services companies, 10x Genomics ranks worse than 86.67% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). 10x Genomics's Average Total Inventories for the
three
months ended in Mar. 2026 was $54.9 Mil. 10x Genomics's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $44.7 Mil.
Hence, 10x Genomics's Days Inventory for the
three
months ended in Mar. 2026 was 112.19.
The historical rank and industry rank for 10x Genomics's Days Inventory or its related term are showing as below:
TXG'
s Days Inventory Range Over the Past 10 Years
Min: 71.29 Med: 141.18 Max: 221.5
Current: 118.6
During the past 9 years, 10x Genomics's highest Days Inventory was 221.50. The lowest was 71.29. And the median was 141.18.
TXG's Days Inventory is ranked worse than 86.67% of 495
companies
in the Healthcare Providers & Services industry
Industry Median: 30.42
vs TXG: 118.60
10x Genomics's Days Inventory
declined
from Mar. 2025 (145.65) to Mar. 2026 (112.19).
Inventory Turnover measures how fast the company turns over its inventory within a year.
10x Genomics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
10x Genomics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.36.
10x Genomics (NAS:TXG) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
10x Genomics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
10x Genomics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
10x Genomics Days Inventory Related Terms
10x Genomics Days Inventory Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Days Inventory vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Days Inventory distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Days Inventory of 112.19 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on 10x Genomics and its competitors. This is 21% below median its historical median of 141.18. Over the past decade, 10x Genomics' Days Inventory has ranged from 71.29 to 221.50. According to the industry distribution chart, 10x Genomics ranks #429 out of 495 companies in the Healthcare Providers & Services industry, placing it in the top 86.7%.
Is 10x Genomics' Days Inventory too high?
10x Genomics' current Days Inventory of 112.19 is 21% below median its 10-year median of 141.18. Over the past 10 years, this metric has ranged from a low of 71.29 to a high of 221.50. The Healthcare Providers & Services industry median Days Inventory is 30.42. 10x Genomics' value of 112.19 is 268.8% above this industry median. Based on the distribution chart, 10x Genomics ranks #429 out of 495 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Days Inventory compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #429 out of 495 companies for Days Inventory. This places 10x Genomics in the lower half of its industry. The industry median Days Inventory is 30.42. 10x Genomics' value of 112.19 is 268.8% above this benchmark. Historically, 10x Genomics' own Days Inventory has ranged from 71.29 to 221.50 over the past decade. While the company's 10-year median is 141.18 vs. the industry median of 30.42, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Healthcare Providers & Services company?
The median Days Inventory among Healthcare Providers & Services companies is 30.42, based on 495 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Days Inventory of 112.19 is 268.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Days Inventory is 30.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Days Inventory is 112.19, which is 21% below median its own 10-year median of 141.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.98, compared to a current price of $39.05 — trading 105.7% above its estimated fair value. The current Days Inventory is 112.19, which is 21% below median its 10-year median of 141.18 and 268.8% above the Healthcare Providers & Services industry median of 30.42. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For 10x Genomics (TXG), the current Days Inventory is 112.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $39.05 is trading 105.7% above its estimated GF Value™ of $18.98.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Days Inventory: 112.19 (21% below median its 10-year median of 141.18)
GF Value™: $18.98 vs. price of $39.05 (105.7% above fair value)
Industry Position: 268.8% above the Healthcare Providers & Services median (#429 of 495)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
